enGene Therapeutics Inc.

8-K Regulation FD disclosure Jul 17, 2026 8-K Director or officer change; Regulation FD disclosure Jul 16, 2026 8-K/A Exit or disposal costs; Director or officer change Jun 18, 2026 10-Q Quarter ended 2026-04-30 Jun 15, 2026 8-K Results of operations (earnings release); Exit or disposal costs; Director or officer change; Regulation FD disclosure; Other events Jun 15, 2026 8-K Shareholder vote results Jun 10, 2026 8-K Director or officer change; Regulation FD disclosure; Other events May 7, 2026 8-K Amended charter or bylaws; Regulation FD disclosure Apr 9, 2026 8-K Entered a material agreement; Terminated a material agreement Mar 9, 2026 10-Q Quarter ended 2026-01-31 Mar 9, 2026 8-K Results of operations (earnings release) Mar 9, 2026 10-K/A Fiscal year ended 2025-10-31 Feb 19, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 21, 2026 8-K Regulation FD disclosure Jan 21, 2026 10-K Fiscal year ended 2025-10-31 Dec 22, 2025 8-K Results of operations (earnings release) Dec 22, 2025 8-K Entered a material agreement; Regulation FD disclosure Nov 14, 2025 8-K Regulation FD disclosure; Other events Nov 12, 2025 8-K Director or officer change Oct 2, 2025 8-K/A Director or officer change Oct 2, 2025 8-K Regulation FD disclosure Sep 30, 2025 10-Q Quarter ended 2025-07-31 Sep 11, 2025 8-K Results of operations (earnings release) Sep 11, 2025 8-K Regulation FD disclosure; Other events Sep 3, 2025 8-K Director or officer change; Regulation FD disclosure Jul 8, 2025 10-Q Quarter ended 2025-04-30 Jun 12, 2025 8-K Results of operations (earnings release) Jun 12, 2025 8-K Director or officer change; Shareholder vote results Jun 10, 2025 8-K Entered a material agreement; Took on a direct financial obligation Jun 9, 2025 8-K Director or officer change; Regulation FD disclosure Jun 4, 2025 10-Q Quarter ended 2025-01-31 Mar 10, 2025 8-K Results of operations (earnings release) Mar 10, 2025 10-K/A Fiscal year ended 2024-10-31 Feb 20, 2025 8-K Entered a material agreement Dec 20, 2024 10-K Fiscal year ended 2024-10-31 Dec 19, 2024 8-K Entered a material agreement; Results of operations (earnings release); Took on a direct financial obligation Dec 19, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Oct 25, 2024 8-K Director or officer change; Regulation FD disclosure; Other events Oct 21, 2024 8-K Regulation FD disclosure; Other events Sep 26, 2024 10-Q Quarter ended 2024-07-31 Sep 10, 2024